The relationship between osteoporosis treatment history and receipt of a second zoledronic acid dose
Konstantelos N, Kim S, Cheung AM, Burden AM, Grootendorst P, Cadarette SM. Osteoporos Int. 2025 Sep 4 [Epub ahead of print].
In this population-based study, we examined the risk of nontuberculous mycobacterial disease associated with immune checkpoint inhibitors among people with cancer. Using a nested case-control design, we identified 184 cases and 714 matched controls; there was no significant association on conditional logistic regression (adjusted odds ratio, 0.51 [95% confidence interval, .17–1.50]; P = .22).
Yan M, Hernandez A, Chan KK, Stanbrook MB, Blanchette PS, Johnston JC, Lee SM, Macdonald L, Richard-Greenblatt M, Marras TK, Brode SK. Clin Infect Dis. 2025: ciae626. Epub 2025 Jan 28.
The ICES website uses cookies. If that’s okay with you, keep on browsing, or learn more about our Privacy Policy.